1-4 of 4
Marion Wiesmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

Ellen Weisberg, Ensar Halilovic, Vesselina G. Cooke, Atsushi Nonami, Tao Ren, Takaomi Sanda, Irene Simkin, Jing Yuan, Brandon Antonakos, Louise Barys, Moriko Ito, Richard Stone, Ilene Galinsky, Kristen Cowens, Erik Nelson, Martin Sattler, Sebastien Jeay, Jens U. Wuerthner, Sean M. McDonough, Marion Wiesmann, James D. Griffin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (10): 2249–2259.
https://doi.org/10.1158/1535-7163.MCT-15-0429
Published: 05 October 2015
View article titled, Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
Open the PDF for Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097 in another window
Includes: Supplementary data
Journal Articles

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Christine Fritsch, Alan Huang, Christian Chatenay-Rivauday, Christian Schnell, Anupama Reddy, Manway Liu, Audrey Kauffmann, Daniel Guthy, Dirk Erdmann, Alain De Pover, Pascal Furet, Hui Gao, Stephane Ferretti, Youzhen Wang, Joerg Trappe, Saskia M. Brachmann, Sauveur-Michel Maira, Christopher Wilson, Markus Boehm, Carlos Garcia-Echeverria, Patrick Chene, Marion Wiesmann, Robert Cozens, Joseph Lehar, Robert Schlegel, Giorgio Caravatti, Francesco Hofmann, William R. Sellers
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2014) 13 (5): 1117–1129.
https://doi.org/10.1158/1535-7163.MCT-13-0865
Published: 05 May 2014
View article titled, Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Open the PDF for Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Abstract A140: Evaluation of prediction of in vivo activity from in vitro combinations: Examples using a MEK1/2 inhibitor combined with docetaxel in NSCLC models.

Paul Martin J. Mcsheehy, Alex Cao, Giordi Caponigro, David Duhl, Brant Firestone, Tom Gesner, Daniel Guthy, Jocelyn Holash, Fred King, Joseph Lehar, Christopher Leroy, Manway Liu, Lilli Petruzzelli, Dale Porter, Daniel Menezes, Anupama Reddy, Johannes Roesel, Christian Schnell, Timothy Smith, Mark Stump, Markus Wartmann, Marion Wiesmann
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A140.
https://doi.org/10.1158/1535-7163.TARG-13-A140
Published: 01 November 2013
View article titled, Abstract A140: Evaluation of prediction of in vivo activity from in vitro combinations: Examples using a MEK1/2 inhibitor combined with docetaxel in NSCLC models.
Journal Articles

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira, Sabina Pecchi, Alan Huang, Matthew Burger, Mark Knapp, Dario Sterker, Christian Schnell, Daniel Guthy, Tobi Nagel, Marion Wiesmann, Saskia Brachmann, Christine Fritsch, Marion Dorsch, Patrick Chène, Kevin Shoemaker, Alain De Pover, Daniel Menezes, Georg Martiny-Baron, Doriano Fabbro, Christopher J. Wilson, Robert Schlegel, Francesco Hofmann, Carlos García-Echeverría, William R. Sellers, Charles F. Voliva
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 317–328.
https://doi.org/10.1158/1535-7163.MCT-11-0474
Published: 08 February 2012
View article titled, Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Open the PDF for Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor in another window
Includes: Supplementary data